In August 2023, the 2023-2028 strategy for the “New Methods” framework was published. The strategy defines the most important objectives for further improvement of the framework over the next five years, including the development of appropriate processes and prioritization criteria for medical devices and procedures.

On August 10, 2023, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 191 and 087 with changes to be implemented no later than October 6, 2023. Five new procedure codes (concerning urogynecology, robotic surgery, and neuromodulation) and six new codes for in-vitro diagnostics were introduced.

In August 2023, the Danish Health Technology Council (Behandlingsråd) decided to conduct evaluations based on completed health technology assessments (HTA) from other countries, adopting their results to the Danish context. This evaluation method will be introduced in addition to the currently used. The Council has already selected the first four HTAs for evaluation.

The Essential Levels of Care defines outpatient specialist care and prosthetic care guaranteed to the Italian population. Although the LEA document was brought in 2017, the national tariffs for outpatient specialist and prosthetic care were approved in April 2023. The tariffs for the 2017 LEA catalog (to be in use from January 2024) were updated with the Decree of the Ministry of Health published in the Official Gazette on 4 August 2023

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Manetti et al. developed a novel framework for assessing readiness in successful Medical Device (MD) development and deployment. Through a four-stage process, the authors developed and validated checklists for both small (21 items) and large (15 items) enterprises. The study identified three key drivers of MD success: R&D assessment strategy, device-outcome measures, and company profiling. Additional retrospective validation with 40 case studies on MDs highlighted the crucial role of early Health Technology Assessment in industry success, varying by enterprise size.

In August 2023, the Basque Office for Health Technology Assessment (OSTEBA) is working on several HTAs, including the evaluations in the cardiovascular, diagnostic imaging, e-health, ENT, ICU/OR, nephrology and urology, IVD, neurovascular, obstetrics and gynecology, surgical procedures, and some other fields.

In June 2023, one assessment was published by the Scottish Health Technologies Group (SHTG) concerning the review of clinical and cost-effectiveness evidence for a digital type 2 diabetes remission program in Scotland. Furthermore, six assessments are currently in development.

Health Information and Quality Authority (HIQA) is an independent statutory authority that develops national health technology assessments to support decision-making in Ireland. In the second quarter of 2023, HIQA published one new Med Tech-related assessment concerning slot-scanning biplanar digital X-ray imaging systems for orthopedic conditions.

In August 2023, NHS England announced the first technology (AposHealth) that will be supported by the MedTech Funding Mandate (MTFM) in 2023/24. MTFM supports NICE-approved, clinically effective, and cost-saving medical devices, diagnostics, and digital technologies, making it mandatory for commissioners and providers to implement them.

In early August 2023, the Polish Agency for Health Technology Assessment and Tariff System (AOTMiT) announced the start of the evaluation of several technologies in men’s health, neuromodulation and in-vitro diagnostics fields.

In July 2023, Health Technology Wales completed one full appraisal on wearable cardioverter defibrillators with the publication of Evidence Appraisal Report (EAR) and Guidance. Furthermore, in July 2023, Health Technology Wales decided to proceed with a full appraisal of radiofrequency renal denervation in the treatment of resistant hypertension based on the published Topic Exploration Report.

On July 25, 2023, the final version of the DRG manual for 2023 was published. Introduced changes relate to the MDC14, coding of gender in patients under three months of age, and performance of acts inconsistent with the declared sex in transsexual patients.